Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content.
A prospective study was designed to determine whether calcium homeostasis and bone mineral content were affected adversely in preterm infants born to mothers receiving long-term antenatal therapy with magnesium sulfate. Preterm infants born to mothers receiving long-term antenatal therapy with magnesium sulfate and requiring prolonged bed rest for preterm labor were compared with infants of mothers not receiving magnesium sulfate but in whom prolonged bed rest was also required. Serum magnesium, calcium, phosphorus, osteocalcin, and parathyroid hormone were measured in infants at 0, 24, 48, and 72 h after delivery. Bone mineral content of the distal radius was measured 1 week postnatally and at term-equivalent postmenstrual age. Maternal serum mineral status indices obtained near delivery and bone indices were compared with those of their infants. The clinical characteristics and morbidities of the infants were similar between groups. We observed significantly greater serum concentrations of magnesium, phosphorus, and osteocalcin during the 72 h after delivery and a lower serum calcium concentration which normalized by 72 h in preterm infants whose mothers were treated with magnesium sulfate compared with infants whose mothers did not receive magnesium sulfate. Both groups, however, had similar radius bone mineral content measurements and anthropometric indices after delivery. These data suggest that although preterm infants born to mothers treated with magnesium sulfate have delayed clearance of magnesium and phosphorus, they have a normalization of serum calcium by 72 h after delivery and no significant differences in bone mineral content after delivery compared with infants whose mothers do not receive magnesium sulfate.
Schanler
R J
RJ
USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, Tex., USA.
Smith
L G
LG
Burns
P A
PA
D000328:Adult; D015519:Bone Density / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000097:blood / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000097:blood / Q000378:metabolism / Q000502:physiology*; D007262:Infusions, Intravenous; D008274:Magnesium / Q000097:blood; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000494:pharmacology*; D008903:Minerals / Q000032:analysis / Q000378:metabolism; D015675:Osteocalcin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood; D010758:Phosphorus / Q000097:blood; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies; D011884:Radius / Q000737:chemistry / Q000378:metabolism / Q000502:physiology; D013997:Time Factors; D015149:Tocolytic Agents / Q000008:administration & dosage / Q000494:pharmacology*
D008903:Minerals; D010281:Parathyroid Hormone; D015149:Tocolytic Agents; D015675:Osteocalcin; D010758:Phosphorus; D008278:Magnesium Sulfate; D008274:Magnesium; D002118:Calcium